Largest review of clinical trials to assess risk of patients using Champix

March 12, 2015, University of Bristol
Largest review of clinical trials to assess risk of patients using Champix

Findings from the largest review of clinical trials to date to determine whether patients prescribed the smoking cessation drug Varenicline (brand name Champix in the UK) are at an increased risk of neuropsychiatric events are published online in the British Medical Journal (BMJ) today. The study was carried out by researchers at the University of Bristol.

The drug, which was first licensed in the UK in 2006, has been shown to be the most clinically effective medicine for reducing nicotine cravings and withdrawal symptoms for short-term abstinence. However, since its introduction there have been concerns over its neuropsychiatric safety following reports of adverse reactions to spontaneous reporting systems. These were reiterated in October 2014 when the US Food and Drug Administration (FDA) decided to keep the black box warning for Varenicline, the agency's strongest safety warning.

A team of researchers, led by Dr Kyla Thomas at the University of Bristol, carried out the first comprehensive published systematic review and meta-analysis to date on the neuropsychiatric effects associated with Varenicline use. Using results from 39 Varenicline studies the team identified a cohort of 10,761 participants that compared the effects of 5,817 patients who had received the maximum dose of 1mg of the drug twice daily and 4,944 patients who had received a placebo.

The findings showed no evidence of an increased risk of suicidal behavior, depression or death in Varenicline users compared with those in placebo groups. Nor did the results show evidence for a variation in depression and by age group, sex, ethnicity, smoking status, or presence or absence of psychiatric illness. The drug was found to be associated with an of sleep disorders including insomnia and abnormal dreams although these side effects are already well recognised and included in patient information leaflets.

In addition, the results showed a 25 per cent reduction in the risk of anxiety although this is likely to be explained by the positive impact of giving up smoking on mental health. Previous research has shown that smokers who quit have a reduction in depression and anxiety compared with those who continue to smoke.

Dr Kyla Thomas, a National Institute for Health Research (NIHR) Clinical Lecturer in Public Health based at Bristol's School of Social and Community Medicine, said: "This study represents the most comprehensive evaluation of adverse effects associated with Varenicline use to date and provides reassurance for both users and prescribers of this medicine.

"Smoking related illnesses cost the NHS approximately £5 billion annually. Ongoing fears regarding Varenicline's safety among prescribers and patients may be reflected in the 25 per cent decrease in prescriptions observed between 2011 and 2013. Findings from this study show that the benefits of using Varenicline to give up smoking outweigh the yet unproven risks of . Therefore, the reduction in prescribing Varenicline should be as much a cause for concern to clinicians, regulatory agencies and policy makers as the unfounded fears regarding the drug's association with suicidal behaviour."

Explore further: Study finds no increased risk of suicide in patients using smoking cessation drugs

More information: 'Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis' by Kyla Thomas et al in the BMJ.

Related Stories

Study finds no increased risk of suicide in patients using smoking cessation drugs

October 10, 2013
A study to assess whether patients prescribed smoking cessation drugs are at an increased risk of suicide, self-harm and treated depression compared with users of nicotine replacement therapy (NRT) has found no evidence of ...

Medication effective in helping smokers quit gradually

February 17, 2015
Among cigarette smokers not willing or able to quit smoking in the next month but willing to reduce with the goal of quitting in the next 3 months, use of the nicotine addiction medication varenicline for 24 weeks compared ...

Varenicline for smoking cessation linked to increased risk of serious harmful cardiac events

July 4, 2011
The use of varenicline to stop smoking is associated with a 72% increased risk of a serious adverse cardiovascular event, states an article in CMAJ (Canadian Medical Association Journal).

Varenicline helps smokers with depression to quit smoking

September 16, 2013
About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder (MDD) have greater difficulty quitting.

Chantix unsuitable for first-line smoking cessation use

November 2, 2011
The poor safety profile of the smoking-cessation drug varenicline (Chantix) makes it unsuitable for first-line use, according to a study published in the Nov. 2 edition of the journal PLoS One, an online publication of the ...

Recommended for you

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.

Study finds no strong evidence that cannabis reduces chronic pain

July 4, 2018
A four-year study suggests medicinal cannabis is not as effective at relieving chronic non-cancer pain as commonly assumed.

Expanding primary care buprenorphine treatment could curb opioid overdose crisis

July 4, 2018
Expanding the availability of medication treatment for opioid use disorder in primary care settings would be a major step toward reducing overdose deaths, write two physicians specializing in addiction medicine and health ...

Chronic pain remains the same or gets better after stopping opioid treatment: study

July 2, 2018
Stopping long-term opioid treatment does not make chronic, non-cancer-related pain worse and, in some cases, makes it better, Washington State University researchers have found.

Pain relief at a lower opioid dose

June 25, 2018
A team of researchers at Johns Hopkins have found that activating nerve cell receptors along two chemical pathways—one that has previously been linked to how the brain senses "itch"—may improve pain relief when combined ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.